Antiviral drug GS-5734 (remdesivir) administration with anti-inflammatory therapy reduces the TMPRSS2 blood level in moderate COVID-19, IL-6 in severe COVID-19 course, and fibrinogen A- and D-dimers in both groups. This evidence concerns the gene IL6 and COVID-19.